Combined oral cyclophosphamide and bevacizumab in heavily pre-treated ovarian cancer.
about
Capecitabine "metronomic" chemotherapy for palliative treatment of elderly patients with advanced gastric cancer after fluoropyrimidine-based chemotherapy.Cyclophosphamide induces bone marrow to yield higher numbers of precursor dendritic cells in vitro capable of functional antigen presentation to T cells in vivo.Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer.Combination antiangiogenic therapy in advanced breast cancer: a phase 1 trial of vandetanib, a VEGFR inhibitor, and metronomic chemotherapy, with correlative platelet proteomicsThe PACOVAR-trial: a phase I/II study of pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant recurrent, pre-treated ovarian cancer.Overcoming platinum resistance in ovarian carcinoma.Primary signet ring cell mucinous ovarian carcinoma: a case report and literature review.Metronomic oral cyclophosphamide (MOC) in the salvage therapy of heavily treated recurrent ovarian cancer patients: a retrospective, multicenter studyDiallyl Disulfide Prevents Cyclophosphamide-Induced Hemorrhagic Cystitis in Rats through the Inhibition of Oxidative Damage, MAPKs, and NF-κB Pathways.The growth and aggressive behavior of human osteosarcoma is regulated by a CaMKII-controlled autocrine VEGF signaling mechanismThe effect of bevacizumab on human malignant melanoma cells with functional VEGF/VEGFR2 autocrine and intracrine signaling loops.Dual Metronomic Chemotherapy with Nab-Paclitaxel and Topotecan Has Potent Antiangiogenic Activity in Ovarian Cancer.Distinct genetic alterations occur in ovarian tumor cells selected for combined resistance to carboplatin and docetaxelThe combination of intravenous bevacizumab and metronomic oral cyclophosphamide is an effective regimen for platinum-resistant recurrent ovarian cancerMetronomic chemotherapy: possible clinical application in advanced hepatocellular carcinomaAntiangiogenic (metronomic) chemotherapy for brain tumors: current and future perspectives.A Phase I/IIa Study of DHP107, a Novel Oral Paclitaxel Formulation, in Patients with Advanced Solid Tumors or Gastric CancerClinical response in patients with ovarian cancer treated with metronomic chemotherapy.Recent advances in anti-angiogenic therapy of cancerThe challenges of integrating molecular imaging into the optimization of cancer therapy.Novel mechanism of synergistic effects of conventional chemotherapy and immune therapy of cancer.Lack of efficacy of combined antiangiogenic therapies in xenografted human melanoma.Genistein Ameliorates Cyclophosphamide - Induced Hepatotoxicity by Modulation of Oxidative Stress and Inflammatory Mediators.Carvacrol attenuates cyclophosphamide-induced oxidative stress in rat kidney.Cyclophosphamide eradicates murine immunogenic tumor coding for a non-self-antigen and induces antitumor immunity
P2860
Q33393811-92D921EC-591A-4C30-AD30-57DB126C3769Q33653210-182249D8-F933-48FE-A067-0ED4A2AD53A0Q33780751-1000C6D5-462F-4C22-9186-4ED68AB0DA9EQ33803564-9E67AB93-2AEF-4583-A942-26F7306D8344Q34052424-6B53AE39-B8C7-436F-BF4B-BE477D9633BBQ34233273-56700390-6D9E-4997-B911-AE84AA6F2F25Q34629495-3E5BC44C-C3D7-4EBC-88C7-43D8D8BC6B52Q34993605-29A3073A-A88A-4742-A4CE-3185722D7A13Q35161300-60275F55-5718-430C-B38E-E536AA2F1DEFQ35362682-175E113D-3850-4AD9-9338-F7E4035FC430Q36172732-A988E74E-6EA9-4839-8716-CF0148DA007BQ36359684-F3A08360-CD5E-443B-8705-2D6E5886EEE8Q36521792-1AE3A24A-7550-4F5F-B734-72BA4D7F9C7DQ37022524-1D09F8C7-0872-4028-9A03-AFE12EDA35A2Q37236004-48946BED-E23D-47A2-936A-68B96F85B6EEQ37528441-E2C4548E-7A76-42C3-B89C-1AC6352200EEQ37672089-DC620DA1-C82D-4ED2-8B2F-2675FBCD7270Q37679904-2EFA48EF-4D41-4D79-97CB-474CAEB7F598Q37852512-1F54EE79-BC8F-4F05-8490-E70F8B232D2DQ37871875-FA74AE11-D6BF-48FF-B3C9-3EAD2EFBBA43Q38083001-12051656-EDC8-438A-BF94-9E4230F373FFQ38659074-3D10B35D-11D5-4B85-A3F2-EBA4EBE511ADQ49809384-D9D2BD7D-C243-4FB2-B9E5-C304AEB93366Q50034647-0776A10E-131A-4900-AC17-F80399E35048Q57149462-3E5F7D7D-10B3-49BC-A8A2-B04E89200DCA
P2860
Combined oral cyclophosphamide and bevacizumab in heavily pre-treated ovarian cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Combined oral cyclophosphamide and bevacizumab in heavily pre-treated ovarian cancer.
@en
Combined oral cyclophosphamide and bevacizumab in heavily pre-treated ovarian cancer.
@nl
type
label
Combined oral cyclophosphamide and bevacizumab in heavily pre-treated ovarian cancer.
@en
Combined oral cyclophosphamide and bevacizumab in heavily pre-treated ovarian cancer.
@nl
prefLabel
Combined oral cyclophosphamide and bevacizumab in heavily pre-treated ovarian cancer.
@en
Combined oral cyclophosphamide and bevacizumab in heavily pre-treated ovarian cancer.
@nl
P2093
P1476
Combined oral cyclophosphamide and bevacizumab in heavily pre-treated ovarian cancer.
@en
P2093
Alfonso Sánchez
Bella Pajares
Elisabeth Pérez
Emilio Alba
José Miguel Jurado
Lorenzo Alonso
P2888
P304
P356
10.1007/S12094-008-0254-7
P577
2008-09-01T00:00:00Z